High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis

類似資料

• Further comments on “High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis”
  著者:: Messori, Andrea, 等
  出版事項: (2019)
• Reply to “High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis” by Messori et al.
  著者:: Farrugia, Albert, 等
  出版事項: (2019)
• Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better
  著者:: Mannucci, Pier Mannuccio
  出版事項: (2010)
• Factor VIII inhibitor and source of replacement therapy
  著者:: Mannucci, Pier Mannuccio, 等
  出版事項: (2012)
• Factor VIII replacement is still the standard of care in haemophilia A
  著者:: Aledort, Louis, 等
  出版事項: (2019)